$LNTH

Lantheus posted $1.54B in 2025 revenue but faces Q4 headwinds. The company plans to refocus on PET diagnostics while exploring options for radiotherapy assets, expecting four FDA approvals in 2026.

PYLARIFY becomes first radiodiagnostic to exceed $1 billion in annual sales with 24% growth, as PSMA-targeted prostate cancer treatments gain significant market momentum.